UK-based Genomics snaps £35M to develop precision tools controlling cancer — TFN

Genomics, a UK-based company specializing in precision healthcare tools, has raised £35 million in a funding round led by F-Prime Capital and Foresight Partners. The investment will be used to develop Genomics' risk estimation technology to prevent common diseases and cancers, expand its workforce, and achieve profitability. The company leverages large-scale genetic information to generate personalized risk assessments for health issues, enabling targeted interventions and personalized screening to prevent or delay disease onset.

Genomics Snaps £35M to Develop Precision Tools for Cancer Prevention

Genomics is a UK-based company founded by four academics from the University of Oxford, including Professor Peter Donnelly, Professor Gil McVean, Dr Gerton Lunter, and Dr Chris Spencer. The company has created proprietary algorithms and databases to link small variations of genomes across large datasets to generate risk assessments for health issues across entire populations. Genomics uses large-scale genetic information to develop precision healthcare tools, working within the new area of genomic prevention. Genomic prevention allows for personalised estimates of risk for common diseases, ahead of actual disease manifestation. This enables targeted interventions and tailored screening to either prevent disease entirely or delay its onset.

Genomics is a UK-based company developing precision healthcare tools using large-scale genetic information to predict and prevent common diseases.

2 years ago

Genomics Snaps £35M to Develop Precision Tools for Cancer Prevention

Covered on